Faeth Therapeutics, Inc.
FTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.43M
Close$
$5.68
71.7% downside
Current Fair Value
71.7% downsideOvervalued by 71.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $113.43 Million |
|---|---|
| Enterprise Value | $87.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.72 |
| Beta | -0.28 |
| Outstanding Shares | 5,643,222 |
Return
| Return on Equity | -113.05% |
|---|---|
| Return on Assets | -103.29% |
| Return on Invested Capital | -109.17% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | -0.08 |
| Price to Sales | - |
| Price to Book Ratio | 0.65 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.44 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.64
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sensei Biotherapeutics Inc
31 employees
CEO: Anand Parikh Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a p...